Verastem Inc
Verastem, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing drugs for the treatment of cancer in the United States. Its product candidates are Avutometinib, an orally available small molecule RAF/MEK clamp that inhibits the ras sarcoma RAF/MEK, ERK mitogen activated pathway kinase pathway which is involved in cell proliferation, migration, transformati… Read more
Verastem Inc (VSTM) - Total Liabilities
Latest total liabilities as of September 2025: $192.38 Million USD
Based on the latest financial reports, Verastem Inc (VSTM) has total liabilities worth $192.38 Million USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Verastem Inc - Total Liabilities Trend (2010–2024)
This chart illustrates how Verastem Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Verastem Inc Competitors by Total Liabilities
The table below lists competitors of Verastem Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
China Wuyi Co Ltd
SHE:000797
|
China | CN¥19.42 Billion |
|
Lily Group Co Ltd
SHG:603823
|
China | CN¥715.05 Million |
|
Quechen Silicon Chemical Co. Ltd.
SHG:605183
|
China | CN¥482.00 Million |
|
Navigator Global Investments Ltd
AU:NGI
|
Australia | AU$164.23 Million |
|
New Providence Acquisition Corp. III Units
NASDAQ:NPACU
|
USA | $12.86 Million |
|
SintokogioLtd
PINK:SILDF
|
USA | $111.57 Billion |
|
Red 5 Limited
PINK:REDLF
|
USA | $444.26 Million |
Liability Composition Analysis (2010–2024)
This chart breaks down Verastem Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.58 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -12.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.09 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Verastem Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Verastem Inc (2010–2024)
The table below shows the annual total liabilities of Verastem Inc from 2010 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $130.43 Million | +41.24% |
| 2023-12-31 | $92.34 Million | +93.76% |
| 2022-12-31 | $47.66 Million | +125.84% |
| 2021-12-31 | $21.10 Million | -45.99% |
| 2020-12-31 | $39.08 Million | -71.66% |
| 2019-12-31 | $137.87 Million | -9.85% |
| 2018-12-31 | $152.94 Million | +376.34% |
| 2017-12-31 | $32.11 Million | +183.33% |
| 2016-12-31 | $11.33 Million | +6.65% |
| 2015-12-31 | $10.62 Million | +7.51% |
| 2014-12-31 | $9.88 Million | +26.46% |
| 2013-12-31 | $7.82 Million | +218.07% |
| 2012-12-31 | $2.46 Million | -96.58% |
| 2011-12-31 | $71.80 Million | +19411.68% |
| 2010-12-31 | $368.00K | -- |